$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer

2021-12-21

2025-07-10

2025-07-10

39

Study Overview

Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer

This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with locally advanced and unresectable or metastatic pancreatic adenocarcinoma. Subjects who are eligible to receive two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), routinely prescribed in combination for pancreatic cancer may be included in this study.

N/A

  • Metastatic Pancreatic Adenocarcinoma
  • Locally Advanced Unresectable Pancreatic Adenocarcinoma
  • OTHER: NEAAR Medical Food
  • NEAAR-001

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2021-09-01  

N/A  

2025-07-17  

2021-10-01  

N/A  

2025-07-18  

2021-10-14  

N/A  

2025-07  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Nonessential Amino Acid Restriction (NEAAR) Medical Food

This is a single arm study in which all subjects will receive NEAAR medical food.

OTHER: NEAAR Medical Food

  • Standardized non-essential amino acid restricted medical food.
Primary Outcome MeasuresMeasure DescriptionTime Frame
Demonstrate tolerability of the NEAAR medical food.The primary endpoint is the rate of the most common Grade 3 and 4 adverse event (AE) related to the NEAAR medical food.Through study completion (average of 6 months)
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Overall response ratesComplete response and partial response using RECIST 1.1Through study completion (average of 6 months)
Duration of best responseThrough study completion (average of 6 months)
Changes in biomarkersAbsolute and relative change from baseline of disease biomarkersThrough study completion (average of 6 months)
Progression-free survivalDuration from radiographic documentation of disease to radiographic documentation of progression or death from any causeThrough study completion (average of 6 months)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Key Inclusion Criteria:
    1. Signed informed consent form (ICF) by subject. 2. Histologically or cytologically confirmed pancreatic adenocarcinoma. 3. Locally advanced and unresectable or metastatic pancreatic adenocarcinoma. 4. Eligible for standard of care treatment with the gem+nabP regimen. 5. 18 years of age or older. 6. Measurable disease as determined by RECIST 1.1 (at least one measurable lesion must not have been irradiated in the past). 7. ECOG Performance Status of ≤ 1. 8. Adequate organ function during screening evaluation 9. Available pancreatic adenocarcinoma tissue samples from a primary or metastatic site that has been biopsied within the last 12 months and provide consent for them to be obtained and analyzed by the study sponsor to assist in determining final eligibility. A minimum of five (ten preferred) formalin fixed paraffin embedded (FFPE) archival or fresh tumor tissue slides are required.
    Key Exclusion Criteria:
    1. Any prior neoadjuvant or adjuvant therapy for pancreatic cancer within 6 months of screening. 2. Any prior therapy for metastatic pancreatic cancer or locally advanced and unresectable pancreatic cancer (except for neoadjuvant or adjuvant therapy as noted above in exclusion criteria 1) 3. Known cerebral metastasis. 4. Diagnosis of another malignancy within the past 2 years (excluding a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancer, or superficial bladder cancer that has been adequately treated, or stage 1 prostate cancer that does not require treatment or requires only treatment with luteinizing hormone-releasing hormone agonists or antagonists if initiated at least 30 days prior to beginning the NEAAR medical food). 5. Body mass index (BMI) <18.5 kg/m2 or >40 kg/m2 or serious or refractive cachexia or anorexia that, in the investigator's judgment, prohibits subjects from having energy or appetite sufficient to reliably engage in a strict medical food regimen for an extended time. 6. Presence of any significant comorbidity including clinically significant cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication), myocardial infarction or unstable angina within the 12 months prior to screening, or any major organ failure. 7. Known hypersensitivity, allergy, or religious restrictions regarding pork or pork-derived products; or known allergy to any of the major food allergens as defined by U.S. law (milk, eggs, fish, Crustacean shellfish, tree nuts, peanuts, wheat, soybeans and sesame); or known allergy or hypersensitivity to , gemcitabine or nab-paclitaxel, PERT products (e.g., Pancreaze), or formulary excipients in these products (refer to the FDA-approved package insert). 8. Major surgery or significant traumatic injury within 14 days of planned start of NEAAR medical food or the anticipation of the need for a major surgical procedure during the study. 9. Unwillingness to consume small quantities of meat products and byproducts (e.g., fish sauce, bone marrow, chicken broth). 10. Diagnosed with an eating disorder, irritable bowel syndrome (IBS), Crohn's disease, ulcerative colitis, or gluten-sensitive enteropathy.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

    • PRINCIPAL_INVESTIGATOR: Andrew Hendifar, MD, Cedars-Sinai

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available

    NPCF Pop up

    Make-A-Will Month

    Snag 6508be92
    Learn More
    Donate Now Online
    Other Ways to Donate